Pulmonary Hypertension

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

By

Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.

Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

Prognostic Model for Mortality in Pediatric Pulmonary Hypertension

By

The Pediatric Index Pulmonary Hypertension Intensive Care Mortality model was compared with the Pediatric Risk of Mortality 2 and 3 models to determine the best model for predicting mortality.

RV Trabecular Complexity Fractal Analysis: Measuring Remodeling in PH

RV Trabecular Complexity Fractal Analysis: Measuring Remodeling in PH

By

The fractal dimension of right ventricular trabecular complexity was a good reproducible marker of remodeling in pulmonary hypertension.

PAH in Congenital Heart Disease: Expert Q&A on Challenges and Advances

PAH in Congenital Heart Disease: Expert Q&A on Challenges and Advances

By

Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

By

Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.

Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

By

After iron supplementation, patients with cyanosis experienced significant improvements in hemoglobin concentration, hematocrit, mean corpuscular volume, ferritin, and transferrin saturation

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

By

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

CTEPH Increases Risk for Sleep Disordered Breathing

CTEPH Increases Risk for Sleep Disordered Breathing

By

Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.

Composite Echo Score Predicts PH in Interstitial Lung Disease

Composite Echo Score Predicts PH in Interstitial Lung Disease

By

The variables for the stepwise echocardiographic score included right ventricular systolic pressure, early pulmonary regurgitation gradient, right atrial area size, tricuspid regurgitation velocity, left ventricle eccentricity index, and right ventricle fractional area change.

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

By

There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

By

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus comorbid with pulmonary arterial hypertension should be considered separate diseases.

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

By

The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

By

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones

PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones

By

Men with higher estradiol and estradiol/testosterone levels had an increased risk for pulmonary arterial hypertension.

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

By

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

By

The "egg-and-banana" sign is a valid computed tomography marker of pulmonary hypertension.

Veno-Arterial Extracorporeal Membrane Oxygenation Improves Survival in Pulmonary Embolism

Veno-Arterial Extracorporeal Membrane Oxygenation Improves Survival in Pulmonary Embolism

By

A protocolized study including initiation of VA-ECMO may reduce mortality in patients with massive PE.

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

By

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

By

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

By

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

By

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

By

In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.

Perioperative Risk Assessment in a Patient With COPD

Perioperative Risk Assessment in a Patient With COPD

By

A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.

Pulmonary hypertension in heart failure with preserved ejection fraction is associated with mortality

Pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) is common in patients undergoing right heart catheterization. Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are predictors of mortality and cardiac hospitalizations in PH-HFpEF.

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

By

Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

By

Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.

Pulmonary Hypertension Mortality Following Cardiac Catheterization

Pulmonary Hypertension Mortality Following Cardiac Catheterization

By

Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.

Clinical Case: Pregnant Woman Presents With Worsening Dyspnea

Clinical Case: Pregnant Woman Presents With Worsening Dyspnea

By

A 32-year-old woman presents to the emergency department with complaints of dyspnea on exertion and near syncopal episodes.

PDE-5 Inhibitor Prescribing Trends Do Not Meet Pulmonary Hypertension Guidelines

PDE-5 Inhibitor Prescribing Trends Do Not Meet Pulmonary Hypertension Guidelines

By

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions are inconsistent with pulmonary hypertension guidelines.

Pulmonary Arterial Hypertension Identified Via Claims-Based Algorithm

Pulmonary Arterial Hypertension Identified Via Claims-Based Algorithm

By

Patients with pulmonary arterial hypertension may be better identified with the use of a claims-based algorithm that includes ICD-9-CM codes, electronic medical records, and more.

Sign Up for Free e-Newsletters